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a b s t r a c t
A liquid chromatographic tandem mass spectroscopy method for the quantiﬁcation of artemisinin in
human heparinised plasma has been developed and validated. The method uses Oasis HLBTM -elution
solid phase extraction 96-well plates to facilitate a high throughput of 192 samples a day. Artesunate
(internal standard) in a plasma–water solutionwas added to plasma (50L) before solid phase extraction.
Artemisinin and its internal standard artesunate were analysed by liquid chromatography and MS/MS
detection on a Hypersil Gold C18 (100mm×2.1mm, 5m) column using a mobile phase containingeywords:
ntimalarial
rtemisinin
igh throughput
iquid chromatography/tandem mass
pectrometry (LC/MS/MS)
olid phase extraction (SPE)
acetonitrile–ammonium acetate 10mM pH 3.5 (50:50, v/v) at a ﬂow rate of 0.5mL/min. The method has
been validated according to published FDA guidelines and showed excellent performance. The within-
day, between-day and total precisions expressed as R.S.D., were lower than 8% at all tested quality control
levels including the upper and lower limit of quantiﬁcation. The limit of detection was 0.257ng/mL for
artemisinin and the calibration rangewas 1.03–762ng/mL using 50L plasma. Themethodwas free from
matrix effects as demonstrated both graphically and quantitatively.. Introduction
Malaria is the most important parasitic disease of humans. An
stimated 250 million people are infected annually with approx-
mately one million deaths each year. The majority of infections
nd deaths occur in sub-Saharan Africa [1,2]. Multi-drug resistant
lasmodium falciparum malaria is today an increasing problem.
rtemisinin (ARN) and its derivatives are still the most effective
ntimalarials available and artemisinin-based combination ther-
py (ACT) is recommended as ﬁrst line treatment for falciparum
alaria worldwide. Recent reports indicate that the artemisinins
ay be in jeopardy with increasing parasite clearance times and
ecreasing effectiveness on the Thai–Cambodian border [3–5].
RN is a naturally occurring sesquiterpene lactone containing an
ndoperoxide group which is extracted from the Chinese herb
rtemisia annua. ARN has very unusual pharmacokinetic prop-
rties with saturable ﬁrst-pass metabolism and time-dependent
harmacokinetics upon repeated administration. Repeated oral
∗ Corresponding author at: Faculty of Tropical Medicine, Mahidol University,
angkok 10400, Thailand. Tel.: +66 23546017.
E-mail address: niklas@tropmedres.ac (N. Lindegardh).
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oi:10.1016/j.jpba.2008.12.014© 2008 Elsevier B.V. Open access under CC BY license.
administration over 5 days is associated with an increase in oral
clearance, explained by an induction of metabolic capacity (i.e.
autoinduction) [6–8]. Maximal ARN concentrations in healthy
volunteers (n=8) and in patients (n=18) after a single oral dose
of 500mg ARN have been reported to be on average 450 and
587ng/mL, respectively [9,10]. The rapid in vivo elimination of ARN
in patients and the unusual clinical pharmacokinetic properties
require a sensitive, robust and accurate bioanalytical method.
Quantiﬁcation of ARN and its derivatives has traditionally been
problematic since the compounds do not have ultraviolet or
ﬂuorescent chromophores. Some analytical methods have reached
a limit of detection of approximately 20–30ng/mL by employing
on-line post-column alkali derivatization before the UV detection
[11–13]. Assays with electrochemical detection (ECD) in a reduc-
tive mode have also been developed utilizing the endoperoxide
conﬁguration of the compounds [14–16]. These methods have
reached a limit of detection of 5–20ng/mL using 0.5–1mL plasma.
The main drawback of ECD in reductive mode is that it requires
rigorously controlled anaerobic conditions and deoxygenation of
biologic samples as well as the mobile phase. This can be very
difﬁcult to establish and maintain practically. Two methods have
been developed using chemiluminescent detection reaching a limit
of detection of 17.5–25ng/mL when using 0.5 and 1mL of serum,
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tion curve was constructed using 50L plasma of each standard.
Quadratic regression with peak area ratio (drug/internal standard
response) against concentrationwith1/concentration2 (x2)weight-
ing was used for quantiﬁcation. Quality control (QC) samples for
Table 1
LC gradient programme.
Time (min) % solvent A % solvent B Flow (L/min)
0 100 0 500
0.8 100 0 500
1.0 0 100 500
2.2 0 100 500
2.3 0 100 1000
3.0 0 100 1000
3.1 100 0 1000Fig. 1. Structures of ARN (A) and ARS (B).
espectively [17,18]. These two methods use post-column alkali
erivatization and ultraviolet irradiation respectively to form the
ydrogen peroxide used for chemiluminescent detection. The
ntroduction of liquid chromatography mass spectrometry
LC–MS) and liquid chromatography tandem mass spectrom-
try (LC–MS/MS) during the last 10 years has revolutionized drug
nalysis and is today considered the gold standard in the analysis
f drugs in biological ﬂuids. To date, only two methods have been
eveloped and validated for drug quantiﬁcation of artemisinin in a
iological matrix using LC–MS/MS [19,20]. The two methods focus
n the quantiﬁcation of artemisinin in rat serum or rat plasma and
ts application in pharmacokinetic studies. Sample pre-treatment
onsisted of liquid–liquid extraction or protein precipitation and
he methods achieved limits of quantiﬁcation of 1 and 4ng/mL
hen using 100L of plasma or serum.
The aim of this work was to develop a sensitive and robust high
hroughput LC–MS/MSmethod using a low plasma volume (50L)
o facilitate detailedhumanpharmacokinetic studies and therapeu-
ic drug monitoring. The method has been validated according to
ublished FDA guidelines [21,22].
. Experimental section
.1. Chemicals and materials
Artemisinin (ARN) and artesunate (ARS) were obtained
rom Guangzhou University of Traditional Chinese Medicine
Guangzhou, China). The structures are shown in Fig. 1. Acetoni-
rile (HPLC-grade), methanol (pro analysis) and HPLC-water were
btained from JT Baker (Phillipsburg, USA). Ammonium acetate
LC–MS grade) was obtained from FLUKA (Sigma–Aldrich, St. Louis,
SA). Ammonium acetate buffer solutions were prepared by dis-d Biomedical Analysis 49 (2009) 768–773 769
solving appropriate amounts of ammonium acetate in HPLC-water
and adjusting pH with acetic acid (Merck Darmstadt, Germany).
2.2. Instrumentation—liquid chromatography mass spectrometry
The LC systemwas an Agilent 1200 system consisting of a binary
LC pump, a vacuum degasser, a temperature-controlled micro well
plate autosampler set at 4 ◦C and a thermostatted column com-
partment set at 40 ◦C (Agilent technologies, Santa Clara, USA). Data
acquisition and quantiﬁcation were performed using Analyst 1.4
(Applied Biosystems/MDS SCIEX, Foster City, USA). The compounds
were analysed on a Hypersil Gold C18 (100mm×2.1mm, 5m)
column protected by a security guard column with a Hypersil Gold
C18 (10mm×2.1mm, 3m) guard cartridge (Thermo electron cor-
poration, USA) under isocratic conditions using a mobile phase
containing acetonitrile–ammonium acetate 10mM pH 3.5 (50:50,
v/v) at a ﬂow rate of 500L/minwith awash out gradient. The com-
plete LC gradient program is listed in Table 1. An API 5000 triple
quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX,
Foster City, USA), with a TurboVTM ionisation source (TIS) inter-
face operated in the positive ion mode, was used for the multiple
reactionmonitoring (MRM) LC–MS/MS analysis. Themass spectro-
metric conditions were optimized for the compounds by infusing a
100ng/mL standard solution in mobile phase at 10L/min using a
Harvard infusion pump (Harvard Apparatus, Holliston, USA) con-
nected directly to the mass spectrometer. An additional tuning
optimization of gas ﬂows and temperatures was performed by con-
tinuously infusing the same standard solution at 10L/min via a “T”
connector into the post-column mobile phase ﬂow (500L/min).
The TIS temperature was maintained at 475 ◦C and the TIS voltage
was set at 4500V. The curtain gas was set to 25.0psi, and the neb-
ulizer (GS1) and TIS (GS2) gases at 55.0 and 60.0psi, respectively.
The CAD gas in the collision cell was set at 5psi. Quantiﬁcation was
performed using selected reactionmonitoring (SRM) for the transi-
tions m/z 300–209 for ARN and 402–267 for ARS. The declustering
potential (DP) was 40.0V for ARN and 50.0V for ARS.
2.3. Preparation of plasma standards
Stock solutions of ARN and ARS (1000g/mL) were prepared in
ethanol stored at −80 ◦C until use.Working solutions of ARN (rang-
ing from 51.4 to 143,000ng/mL) were prepared by serial dilution of
the stock solution in ethanol–water (50–50, v/v). A 100L aliquot
of eachworking solution (ARN)was added to blank heparin plasma
(4900L) kept on ice to yield spiked calibration standards at six
different concentrations ranging from 1.03 to 762ng/mL. A calibra-4.6 100 0 750
4.7 100 0 500
5.1 100 0 500
Solvent A: acetonitrile–aqueous ammonium acetate 10mM pH 3.5 (50–50, v/v).
Solvent B: methanol–acetonitrile (75–25, v/v).
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100/50ng/mLARN/ARS solution at 10L/min by aHarvard infusion
pump through a T-connectorwas introduced to themass spectrom-
eter while samples to be tested were injected.
Table 2
Back-calculated concentrations of standard curves for artemisinin in human plasma.
Nominal concentration
(ng/mL)
1.03 3.85 14.4 54.2 203 762
Average (n=8) 1.02 3.88 14.6 54 201 765
S.D. 0.01 0.15 0.35 3.21 5.6 19.6
CV (%) 1.28 3.95 2.39 5.99 2.78 2.56
Accuracy 99.6 101 101 98.7 99.2 100
Table 3
Inter-, intra- and total-assay precision (ANOVA) for artemisinin in human plasma.70 N. Lindegardh et al. / Journal of Pharmaceu
etermination of accuracy and precision in heparin plasma at three
oncentrations (2.89, 40.7 and 571ng/mL) were prepared in the
ame manner as the calibration standards and stored at −80 ◦C
ntil analysis. The amount of stock solution in all spiked samples
as kept at 2% of the total sample volume to minimize any sys-
ematic errors between real samples and standards. The calibration
tandards and QC samples were stored in cryovials at −80 ◦C until
nalysis. A working solution of ARS (5000ng/mL) was prepared in
thanol and stored in 200L aliquots at −80 ◦C until use. On the
ay of assay thisworking solutionwas dilutedwith a plasma–water
olution (50–50, v/v containing sodium ﬂuoride/potassium oxalate
/3mg/mL) to 20.4ng/mL and kept on ice until use.
.4. Analytical procedure
An eppendorf stream multistepper was used to add 150L ice-
old internal standard solution (20.4ng/mL ARS in plasma–water
50–50, v/v) containing sodium ﬂuoride/potassium oxalate
/3mg/mL) to 50L plasma in a 96-well plate kept on ice. The
amples were loaded onto a conditioned -elution HLB SPE
6-well plate (Waters, USA). All steps in the solid phase extraction
SPE) procedure were conducted using a 12-channel pipette as
ollows: the SPEwells were activated and conditioned using 750L
cetonitrile followed by 750L methanol and 200L water. The
amples (200L) were loaded onto the SPE plate and drawn
hrough using a low vacuum. The SPE wells were washed using
00L water drawn through using medium vacuum. Full vacuum
as applied brieﬂy before the SPE column tips were wiped dry
ith tissue paper and a 96-collection plate (0.5mL) was inserted
nto the vacuum manifold. The wells were eluted using 100L
ethanol–acetonitrile (90:10, v/v) drawn through using a low
acuum followed by 100L water. The SPE eluates were mixed
rieﬂy on a mixmateTM (Eppendorf, Germany) at 600 rpm and
quilibrated at 4 ◦C overnight before analysis. 5L was injected
nto the LC–MS/MS system.
.5. Validation
Linearity and the calibration model were evaluated using cal-
bration curves obtained over 4 days. Precision and accuracy
hroughout the calibration range were evaluated by analysis of 5
eplicates of quality control (QC) samples at three different concen-
rations daily for 4 days. Lower and upper limits of quantiﬁcations
ere evaluated by analysis of three replicates daily for 4 days.
arry-over effects for all the compounds were evaluated by injec-
ion of blank samples directly after injection of the highest point in
he calibration curve. Over-curve dilution was evaluated by anal-
sis of three replicates (2860ng/mL ARN diluted ﬁve times with
lank human heparin plasma) daily for 4 days. Stability of stock
olutions in ethanol was evaluated at −80 ◦C. Stability of ARN
n human heparin plasma was evaluated over three freeze/thaw
ycles, at ambient temperature for 2h and at 4 ◦C for 48h. Bench-
op stability of ARN in the autosampler was evaluated for 24h. The
oncentrations were determined with 1/concentration2 weighted
uadratic regression using a calibration curve prepared each day.
ntra-, inter- and total-assay precisions were calculated using anal-
sis of variance (ANOVA). Selectivity was evaluated by analysis
f blank heparin plasma from six different donors. The poten-
ial interference between ARN and the internal standard ARS was
lso evaluated. Recovery was determined by comparing the peak
rea for extracted QC samples with direct injected solution con-
aining the same nominal concentration of the compounds as
he QC samples after SPE. Matrix effects were evaluated thor-
ughly using blank heparin plasma from six different donors. A
uantitative estimation of the matrix effects was obtained by com-
aring the peak area for samples spiked in elution solution withFig. 2. Collision-induced dissociation mass spectra for ARN (a) and ARS (b). For
experimental conditions see Section 2.2.
extracted blank matrix spiked with the same nominal concentra-
tion of the compounds. A qualitative visualization of the matrix
effects was obtained through post-column infusion experiments as
described by others. Brieﬂy, a continuous post-column infusion ofInter-assay (%) Intra-assay (%) Total-assay (%)
QC 1: 2.89ng/mL 5.46 3.98 4.25
QC 2: 40.7ng/mL 3.24 2.62 2.72
QC 3: 571ng/mL 4.35 3.32 3.51
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Table 4
Inter-, intra- and total-assay precision (ANOVA) for lower limit of quantiﬁcation, upper limit of quantiﬁcation and diluted over-curve samples for artemisinin in humanplasma.
Inter-assay CV (%) Intra-assay CV (%) Total-assay CV (%) Accuracya (%)
LLOQ: 1.03ng/mL 2.82 3.53 3.35 101
ULOQ: 762ng/mL 8.02 2.16 4.57 99
Over-curve: diluted to 572ng/mL 3.56 3.57 3.57 104
a Mean accuracy over all 4 validation days.
Table 5
Matrix effects. Artemisinin (ARN) and internal standard (ARS) spiked in extracted blank human plasma vs. spiked in elution solution.
Blank A Blank B Blank C Blank D Blank E Blank F Average S.D. CV (%)
ARN (QC1): 2.89ng/mL 105 107 110 106 101 108 106 3.0 2.9
ARS (QC1): 20.4ng/mL 109 110 106 108 109 116 110 3.4 3.1
Normalized response 0.96 0.98 1.04 0.99 0.93 0.93 0.97 0.04 4.1
A 107
A 115
N 0.9
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DRN (QC3): 571ng/mL 102 108 106
RS (QC3): 20.4ng/mL 109 107 112
ormalized response 0.93 1.01 0.94
. Results and discussion
Both electrospray (TIS) and atmospheric pressure chemical
onisation (APCI) have been used previously for quantiﬁcation
f artemisinin derivatives in biological ﬂuids [19,23–28]. Previ-
us investigations revealed that TIS was superior to APCI for the
uantiﬁcation of artesunate and dihydroartemisinin (DHA) mainly
ecause of improved linearity [28]. The TIS interface provided
ood sensitivity for ARN and the mass spectra for both ARN and
RS displayed the base peak for the ammonium adduct (m/z 300)
ith signiﬁcantly lower intensity for the protonated molecular ion
M+H]+ (m/z 283). The collision-induced dissociation (CID) mass
pectra for ARN and ARS are shown in Fig. 2a and b. Amobile phase
f acetonitrile–ammonium acetate 10mM pH 3.5 (50:50, v/v) pro-
ided adequate retention and separation of ARN and the internal
tandard ARS. Duringmethod development and pre-validation ARS
nd DHA were evaluated as potential internal standards. The per-
ormance (i.e. with respect to intra- and inter-assay precision) was
lightly better when using ARS compared to DHA. ARS elutedmuch
loser (1.75min) to ARN (2.06) with the current LC settings than
HA (1.38) making ARS more suitable to compensate for unfore-
Fig. 3. Overlays from injection of six extracted blank human plasma sample106 108 106 2.2 2.1
112 116 112 3.4 3.0
2 0.95 0.93 0.95 0.03 3.3
seen matrix effects. Another advantage of ARS rather than DHA
as the internal standard was the better stability [29]. The Oasis
-elution HLB SPE 96-well plate facilitates low elution volumes
and is designed for low sample volumes. Different elution solution
compositions were evaluated to maximize recovery and facilitate
direct injection fromthe eluatewithout causingbandbroadeningof
the peaks. A 100L of the elution solution (methanol–acetonitrile,
90–10, v/v) completely eluted the compounds from the SPE wells
and the subsequent step using 100L of water was drawn through
the SPE wells to dilute the organic solvent content and optimize
compatibility with the LC–MS/MS system.
3.1. Validation
The calibration range was determined to 1.03–762ng/mL for
ARNwhich includes the averagemaximal concentration after a sin-
gle oral dose of 500mg ARN in patients and healthy volunteers
[9,10]. Back-calculated concentrations for the calibration standards
were used to verify that themost appropriate regressionmodelwas
used (Table 2). A quadratic regressionmodel with 1/concentration2
(x2) weighting generated an evenly distributed low error over
s during post-column infusion 10L/min of ARN/ARS, 100/50ng/mL.
772 N. Lindegardh et al. / Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 768–773
a sing
t
d
i
u
L
a
b
b
r
N
c
c
p
r
s
b
T
v
a
r
b
f
t
t
i
b
c
g
ﬁ
s
e
b
a
a
l
A
a
d
g
i
160mg ARN (new formulation) coformulated with 720mg piper-
aquine. The full results will be described in full elsewhere. Plasma
samples were collected for up to 12h after dose and Fig. 4 shows a
chromatogram from a healthy volunteer sample taken 12h after anFig. 4. Chromatogram from a plasma sample (3.49ng/mL ARN) taken 12h after
he whole calibration range with excellent reproducibility. Three
ifferent QC levels were evaluated over 4 consecutive days show-
ngwithin-day, between-day and total-assay precisions (calculated
singANOVAsingle factor) below6% for all threeQC levels (Table 3).
imit of detection was determined to 0.257ng/mL for artemisinin
s it generated a peak that was clearly distinguishable from the
ackground noise (i.e. >3 times the background variability seen in
lank plasma). The LLOQ and ULOQwere set to 1.03 and 762ng/mL,
espectively, resulting in high precision and accuracy (Table 4).
either ARN nor the internal standard produced any detectable
arry-over after three injections of ULOQ. Plasma samples with
oncentrations above ULOQ could be diluted ﬁve times with blank
lasma to fall within the calibration range without reduced accu-
acy or precision (Table 4). Blank human plasma from six different
ources showed no interference with ARN. Interfering signals from
lank plasma contributed less than 20% of the ARN signal at LLOQ.
here was no interference of ARN on the internal standard or vice
ersa. The recovery (including matrix effects) was high (110–125%)
t all tested concentrations for ARN and the internal standard. The
eason for the recovery being higher than 100% is partly explained
y a small enhancement of the signal and partly explained by the
act that a small fraction of the elution volume (150L) remains
rapped on the SPE column. A small enhancement for ARN and
he internal standard could be detected when references in neat
njection solventwere comparedwith references in extracted blank
iological matrix. The normalized matrix effects (ARN/ARS) were
lose to 1 with a low variation in accordance with international
uidelines (Table 5) [22]. Post-column infusion experiments con-
rmed the absence of regions with severe matrix effects (i.e. no
harp drops or increases in the response) for blank human plasma
xtracted with the developed method (Fig. 3). ARN was found sta-
le in heparinised plasma during three freeze/thaw cycles and for
t least 2h at ambient temperature or for up to 48h when stored
t 4 ◦C (i.e. >85% recovered). The stock solution was stable for at
east 4h at ambient temperature and for up to 14 days at −80 ◦C.
RN is stable for at least 4h when prepared for extraction and for
t least 24h in the autosampler. The stability of the artemisinin
erivates varies considerably in different sources of plasma and
enerally poor thermal stability is displayed [29,30]. The stabil-
ty in plasma is signiﬁcantly improved when stored on ice andle oral dose of 160mg ARN from a healthy volunteer. Overlay of blank plasma.
the entire analytical process (including sample preparation for QC,
standards and clinical samples) was therefore performed on ice
[30].
3.2. Clinical applicability
This assay was implemented for the analysis of clinical sam-
ples from a bioequivalence study in healthy volunteers in Vietnam.
The analysed samples were from a single-centre, cross-over study
in 15 healthy subjects to determine the relative bioavailability of
artemisinin following oral administration of four different formu-
lations, each dose occasion separated by a washout period of 3
weeks. The four arms were; single oral administration of 160mg
ARN (new formulation), 160mg ARN (standard Vietnamese for-
mulation), 500mg ARN (standard Vietnamese formulation), andFig. 5. Concentration–time proﬁles from one healthy volunteer after four different
treatments. T1: 160mg ARN (new formulation), T2: 160mg ARN (standard Viet-
namese formulation), T3: 500mg ARN (standard Vietnamese formulation), and T4:
160mg ARN (standard Vietnamese formulation) coformulated with 720mg piper-
aquine.
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(2008) 61–68.N. Lindegardh et al. / Journal of Pharmaceu
raldoseofARN(160mg,newformulation). Thechromatogramdis-
lays anARNconcentration of 3.49ng/mLwith anoverlay of a blank
lasma sample. None of the measured ARN concentrations at 12h
fter dose fell below the LLOQ and only one sample out of the 900
nalysed was above the ULOQ displaying excellent clinical applica-
ility for the developed method. The sample above the ULOQ was
uccessfully diluted to fall within the calibration range. Fig. 5 dis-
lays concentration–time proﬁles for the different treatment arms
or one healthy volunteer.
. Conclusion
A sensitive high throughput LC–MS/MSmethod for the determi-
ation of ARN in human heparin plasma has been developed and
alidated. The assay presented here is the ﬁrst validated method to
uantify ARN in human plasma using LC–MS/MS. The total analy-
is time for two batches (192 samples) is less than 24h. The assay
ad a high recovery and proved to be highly sensitive with excel-
ent reproducibility. This method requires only 50L of plasma
nd ARN is stable in human plasma for up to 2h at ambient tem-
erature but will remain stable for considerably longer if kept
n ice. The developed method is shown to be ideal for pharma-
okinetic studies and will hopefully provide increased knowledge
bout the clinical features of artemisinin as stability, sensitivity
nd accuracy has been improved compared to previously published
ssays.
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